Literature DB >> 23483357

Biphasic increase of gap junction coupling induced by dipyridamole in the rat aortic A-10 vascular smooth muscle cell line.

Daniela Begandt1, Almke Bader, Lutz Dreyer, Natalie Eisert, Thilo Reeck, Anaclet Ngezahayo.   

Abstract

The rat aortic smooth muscle cell line A-10 was used to investigate the effect of dipyridamole on the gap junction coupling of smooth muscle cells. The scrape loading/dye transfer (SL/DT) technique revealed that dipyridamole concentrations between 5 μM and 100 μM significantly increased gap junction coupling. The adenosine receptor antagonist MRS 1754, as well as the PKA inhibitors Rp-cAMPS and H-89 were able to inhibit the dipyridamole-related increase in coupling, while forskolin and Br-cAMP also induced an enhancement of the gap junction coupling. Regarding the time-dependent behaviour of dipyridamole, a short-term effect characterised by an oscillatory reaction was observed for application times of less than 5 h, while applications times of at least 6 h resulted in a long-term effect, characterised by a constant increase of gap junction coupling to its maximum levels. This increase was not altered by prolonged presence of dipyridamole. In parallel, a short application of dipyridamole for at least 15 min was found to be sufficient to evoke the long-term effect measured 6 h after drug washout. We propose that in both the short-term and long-term effect, cAMP-related pathways are activated. The short-term phase could be related to an oscillatory cAMP effect, which might directly affect connexin trafficking, assembly and/or gap junction gating. The long-term effect is most likely related to the new expression and synthesis of connexins. With previous data from a bovine aortic endothelial cell line, the present results show that gap junction coupling of vascular cells is a target for dipyridamole.

Entities:  

Year:  2013        PMID: 23483357      PMCID: PMC3660691          DOI: 10.1007/s12079-013-0196-4

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  50 in total

1.  Formation of heteromeric gap junction channels by connexins 40 and 43 in vascular smooth muscle cells.

Authors:  D S He; J X Jiang; S M Taffet; J M Burt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 2.  Adenosine receptor desensitization and trafficking.

Authors:  Stuart Mundell; Eamonn Kelly
Journal:  Biochim Biophys Acta       Date:  2010-06-13

Review 3.  Vascular gap junctions in hypertension.

Authors:  Xavier F Figueroa; Brant E Isakson; Brian R Duling
Journal:  Hypertension       Date:  2006-10-02       Impact factor: 10.190

4.  Cyclic AMP induces rapid increases in gap junction permeability and changes in the cellular distribution of connexin43.

Authors:  R C Burghardt; R Barhoumi; T C Sewall; J A Bowen
Journal:  J Membr Biol       Date:  1995-12       Impact factor: 1.843

5.  Vascular abnormalities in mice lacking the endothelial gap junction proteins connexin37 and connexin40.

Authors:  Alexander M Simon; Andrea R McWhorter
Journal:  Dev Biol       Date:  2002-11-15       Impact factor: 3.582

6.  Endothelial cell-specific knockout of connexin 43 causes hypotension and bradycardia in mice.

Authors:  Y Liao; K H Day; D N Damon; B R Duling
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

7.  Enhanced functional gap junction neoformation by protein kinase A-dependent and Epac-dependent signals downstream of cAMP in cardiac myocytes.

Authors:  Satoshi Somekawa; Shigetomo Fukuhara; Yoshikazu Nakaoka; Hisakazu Fujita; Yoshihiko Saito; Naoki Mochizuki
Journal:  Circ Res       Date:  2005-08-25       Impact factor: 17.367

Review 8.  Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters.

Authors:  Marzena Podgorska; Katarzyna Kocbuch; Tadeusz Pawelczyk
Journal:  Acta Biochim Pol       Date:  2005-10-25       Impact factor: 2.149

9.  Defective Cx40 maintains Cx37 expression but intact Cx40 is crucial for conducted dilations irrespective of hypertension.

Authors:  Alexander Jobs; Kjestine Schmidt; Volker J Schmidt; Indra Lübkemeier; Toon A B van Veen; Armin Kurtz; Klaus Willecke; Cor de Wit
Journal:  Hypertension       Date:  2012-10-22       Impact factor: 10.190

Review 10.  Translational therapeutics of dipyridamole.

Authors:  Hyung-Hwan Kim; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-03       Impact factor: 8.311

View more
  4 in total

1.  Gold nanoparticle-mediated (GNOME) laser perforation: a new method for a high-throughput analysis of gap junction intercellular coupling.

Authors:  Daniela Begandt; Almke Bader; Georgios C Antonopoulos; Markus Schomaker; Stefan Kalies; Heiko Meyer; Tammo Ripken; Anaclet Ngezahayo
Journal:  J Bioenerg Biomembr       Date:  2015-08-27       Impact factor: 2.945

2.  Dipyridamole-related enhancement of gap junction coupling in the GM-7373 aortic endothelial cells correlates with an increase in the amount of connexin 43 mRNA and protein as well as gap junction plaques.

Authors:  Daniela Begandt; Almke Bader; Linda Gerhard; Julia Lindner; Lutz Dreyer; Barbara Schlingmann; Anaclet Ngezahayo
Journal:  J Bioenerg Biomembr       Date:  2013-06-26       Impact factor: 2.945

3.  Adenosine receptors regulate gap junction coupling of the human cerebral microvascular endothelial cells hCMEC/D3 by Ca2+ influx through cyclic nucleotide-gated channels.

Authors:  Almke Bader; Willem Bintig; Daniela Begandt; Anne Klett; Ina G Siller; Carola Gregor; Frank Schaarschmidt; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Stefan W Hell; Anaclet Ngezahayo
Journal:  J Physiol       Date:  2017-02-14       Impact factor: 5.182

4.  Exendin-4 overcomes cytokine-induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets.

Authors:  Nikki L Farnsworth; Rachelle Walter; Robert A Piscopio; Wolfgang E Schleicher; Richard K P Benninger
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.